Current management of primary cutaneous CD30+ T-cell lymphoproliferative disorders

ONCOLOGY

Volumn 23, Issue 13, 2009, Pages

  Kadin, Marshall E ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEXAROTENE; CARMUSTINE; CHLORMETHINE; CORTICOSTEROID; CUTANEOUS LYMPHOCYTE ASSOCIATED ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPITHELIAL MEMBRANE ANTIGEN; ETOPOSIDE; GAMMA INTERFERON; GAMMA1B INTERFERON; IMIQUIMOD; INTERLEUKIN 12; METHOTREXATE; PENTOSTATIN; PREDNISONE; PSORALEN; RETINOID; STEROID; TETRACYCLINE; VINCRISTINE;

AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BODY WEIGHT; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CD30+ T CELL LYMPHOPROLIFERATIVE DISEASE; CHILD; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG MEGADOSE; FATIGUE; GASTROINTESTINAL CRAMP; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; IMMUNOPATHOLOGY; LARGE CELL LYMPHOMA; LEUKOPENIA; LIVER FIBROSIS; LOW DRUG DOSE; LYMPHOMATOID PAPULOSIS; LYMPHOPROLIFERATIVE DISEASE; MYCOSIS FUNGOIDES; NAUSEA; PROGNOSIS; PUVA; SIDE EFFECT; SYMPTOMATOLOGY; T CELL LYMPHOMA; T LYMPHOCYTE; ULTRAVIOLET B RADIATION;

EID: 73449146020     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Macaulay WL: Lymphomatoid papulosis: a continuing self-healing eruption, clinically benign-hematologically malignant. Arch Dermatol 97:23-31, 1968.
2. Liu HJL, Hoppe RT, Kohler S, et al: CD30+ cutaneous lymphoproliferative disorders: The Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. J Am Acad Dermatol 1049-1058, 2003.
3. Bekkenk MW, Geelen FAMJ, Vader PC, et al: Primary and secondary cutaneous CD30+ lymphoproliferative disorders: Report from the Dutch Cutaneous Lymphoma group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 95:3653-3661, 2000.
4. Wang HH, Myers T, Lach LJ, et al: Increased risk of lymphoid and non-lymphoid malignancies in patients with lymphomatoid papulosis. Cancer 86:1240-1245,1999.
5. Kadin ME: Primary Ki-1 positive anaplastic large-cell lymphoma: A distinct clinicopathologic entity. Ann Oncol 5(suppl 1):25-30, 1994.
6. Le Deley M-C, Reiter A, Williams D, et al: Prognostic factors in childhood anaplastic large cell lymphoma: Results of a large European intergroup study. Blood 111:1560-1566, 2008.
7. De Bruin PC, Beljaards RC, van Heerde P, et al: Differences in clinical behavior and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T-cell or null-cell phenotype. Histopathology 23:127-135, 1993.
8. Franchina M, Kadin ME, Abraham LW: Polymorphism of the CD30 promoter microsatellite repressive element is associated with development of primary cutaneous lymphoproliferative disorders. Cancer Epidemiol Biomarkers Prev 14:1322-1325, 2005.
9. Njisten T, Curiel C, Kadin ME: Lymphomatoid papulosis in children. Arch Dermatol 240:306-311, 2004.
10. Fletcher CL, Orchard GE, Hubbard V, et al: CD30(+) cutaneous lymphoma in association with atopic eczema. Arch Dermatol 140:449-454, 2004.
11. Feldman AL, Law M, Remstein ED, et al: Recurrent translocations involving the IRF4 locus in peripheral T-cell lymphomas. Leukemia 23:574-580, 2009.
12. Beljaards RC, Willemze R: The prognosis of patients with lymphomatoid papulosis associated with malignant lymphomas. Br J Dermatol 126:596,-602,1992.
13. Chott A, Vonderheid EC, Olbricht S, et al: The same dominant T cell clone is present in multiple regressing skin lesions and associated T cell lymphomas of patients with lymphomatoid papulosis. J Invest Dermatol 106:696-700,1996.
14. Basarab T, Fraser-Andrews EA, Orchard G, et al: Lymphomatoid papulosis in association with mycosis fungoides: A study of 15 cases. Br J Dermatol 139:680-688, 1998.
15. Wang HH, Lach L, Kadin ME: Epidemiology of lymphomatoid papulosis. Cancer 70:2951-2957, 1992.
16. Wang HH, Myers T, Lach LJ, et al: Increased risk of lymphoid and non-lymphoid malignancies in patients with lymphomatoid papulosis. Cancer 86:1240-1245, 1999.
17. Knaus P, Lindemann D, De Coteau JF, et al: A dominant inhibitory mutant of the type II TGF- β receptor in the malignant progression of a cutaneous T-cell lymphoma. Mol Cell Biol 16:3480-3489, 1996.
18. Schiemann WP, Pfeifer WM, Levi E, et al: A deletion in the gene for transforming growth factor-beta type I receptor abolishes growth regulation by transforming growth factor-beta in a cutaneous T cell lymphoma. Blood 94:2854-2861, 1999.
19. Vonderheid EC, Sajjadian A, Kadin ME: Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol 34:470-481, 1996.
20. Bangert CA, Costner MI: Methotrexate in dermatology. Dermatol Ther 20:216-228, 2007.
21. Yagi H, Tokura Y, Furukawas F, et al: Th2 cytokine mRNA expression in primary cutaneous CD30-postiive lymphoproliferative disorders: Successful treatment with recombinant interferon-gamma. J Invest Dermatol 107:827-832, 1996.
22. Schmuth M, Topar G, Illersperger B, et al: Therapeutic use of interferon-alpha for lymphomatoid papulosis. Cancer 89:1603-1610, 2000.
23. Krathen RA, Ward S, Duvic M: Bexarotene is a new treatment option for lymphomatoid papulosis. Dermatology 206:142-147, 2003.
24. Drews R, Samel A, Kadin ME: Lymphomatoid papulosis and anaplastic large cell lymphomas of the skin. Semin Cutan Med Surg 19:109-117, 2000.
25. Willemze R, Beljaards RC: Spectrum of parimary cutaneous CD30 (Ki-1)- positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment. J Am Acad Dermatol 28:973-980,1993.
26. Beljaards RC, Kaudewitz P, Berti E, et al: Primary cutaneous CD30-positive large cell lymphoma: Definition of a new type of cutaneous lymphoma with a favorable prognosis. A European Multicenter Study of 47 patients. Cancer 71:2097-2104, 1993.
27. Paulli M, Berti E, Rosso R, et al: CD30/Ki-1+ lymphoproliferative disorders of the skin: Clinicopathologic correlation and statistical analysis of 86 cases. J Clin Oncol 12:1343-1354, 1995.
28. Brice R, Cazals D, Mounier N, et al: Primary cutaneous large-cell lymphoma. Analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas. Groupe dEtude des Lymphomas de lAdulte. Leukemia 12:213-219, 1998.
29. Rijlaarsdam JU, Hijgens PC, Beljaards RC, et al: Oral etoposide in treatment of cutaneous T-cell lymphoma. Br J Dermatol 127:524-528,1992.
30. Didona B, Benucci R, Amerio P, et al. Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (Aldara). Br J Dermatol 150:1198-201, 2004.
31. Duvic M, Reddy SA, Pinter-Brown L, et al: A phase II study of SGN-30 (anti-CD30 monoclonal antibody) in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res 15:6217-6224, 2009.
32. Shipp MA: Prognostic factors in aggressive non-Hodgkins lymphoma: Who has high-risk disease? Blood 83:1165-1173, 1994.